Coya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results

Coya Therapeutics (NASDAQ:COYA) announced its earnings results on Tuesday. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.11), FiscalAI reports. The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.11 million. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%.

Coya Therapeutics Trading Up 2.8%

Shares of COYA traded up $0.09 during mid-day trading on Wednesday, hitting $3.25. The company’s stock had a trading volume of 17,044 shares, compared to its average volume of 178,811. The firm has a 50-day simple moving average of $4.37 and a 200 day simple moving average of $4.60. The firm has a market capitalization of $76.25 million, a P/E ratio of -3.04 and a beta of 0.70. Coya Therapeutics has a 1-year low of $2.72 and a 1-year high of $6.62.

Analyst Ratings Changes

Several brokerages recently weighed in on COYA. Roth Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Coya Therapeutics in a report on Monday, August 24th. HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a research note on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Thursday, October 15th. Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Finally, BTIG Research restated a “buy” rating and issued a $16.00 target price on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

About Coya Therapeutics

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.